Literature DB >> 33670477

Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience.

Carla de Sanctis Pecora1, Danielle Shitara1.   

Abstract

Unilateral peripheral facial nerve palsy jeopardizes quality of life, rendering psychological consequences such as low self-esteem, social isolation, anxiety, and depression. Among therapeutical approaches, use of Botulinum toxin type A (BoNT-A) on the nonparalyzed side has shown promising results and improvement of quality of life. Nevertheless, the correct technique is paramount, since over-injection of the muscles can result in lack of function, leading to a "paralyzed" appearance, and even worse, functional incompetence, which may cause greater distress to patients. Therefore, the objective of this article is to provide a practical guideline for botulinum toxin use in facial palsy. To this aim, adequate patient assessment, BoNT-A choice, injection plan and dosage, and injection techniques are covered.

Entities:  

Keywords:  botulinum toxin A; facial asymmetry; facial palsy; facial paralysis; incobotulinum-toxin A; neurotoxin

Mesh:

Substances:

Year:  2021        PMID: 33670477      PMCID: PMC7923088          DOI: 10.3390/toxins13020159

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  37 in total

1.  Genotype analysis of Giardia isolated from asymptomatic children in northern Portugal.

Authors:  André A Almeida; Maria L Delgado; Sónia C Soares; António O Castro; Maria J Moreira; Carla M Mendonça; Nuno B Canada; José M Correia Da Costa
Journal:  J Eukaryot Microbiol       Date:  2006       Impact factor: 3.346

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Facial nerve grading system.

Authors:  J W House; D E Brackmann
Journal:  Otolaryngol Head Neck Surg       Date:  1985-04       Impact factor: 3.497

4.  Evaluation of the body image of patients with facial palsy before and after the application of botulinum toxin.

Authors:  Viviane F de Carvalho; Ana Paula S Vieira; Andre O Paggiaro; Alessandra G Salles; Rolf Gemperli
Journal:  Int J Dermatol       Date:  2019-03-25       Impact factor: 2.736

5.  Botulinum toxin in the treatment of facial synkinesis and hyperkinesis.

Authors:  Roberto Filipo; Irma Spahiu; Edoardo Covelli; Maria Nicastri; Gian Antonio Bertoli
Journal:  Laryngoscope       Date:  2012-01-17       Impact factor: 3.325

6.  Validation of the Synkinesis Assessment Questionnaire.

Authors:  Ritvik P Mehta; Mara WernickRobinson; Tessa A Hadlock
Journal:  Laryngoscope       Date:  2007-05       Impact factor: 3.325

7.  Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg.

Authors:  Luca Carli; Cesare Montecucco; Ornella Rossetto
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

8.  IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery.

Authors:  Mihail A Akulov; Ol'ga R Orlova; Aleksandra S Orlova; Dmitrij J Usachev; Vadim N Shimansky; Sergey V Tanjashin; Svetlana E Khatkova; Anna V Yunosha-Shanyavskaya
Journal:  J Neurol Sci       Date:  2017-08-24       Impact factor: 3.181

9.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

10.  One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA.

Authors:  Carla de Sanctis Pecora
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-02-05
View more
  1 in total

1.  Ultrasound Imaging of the Facial Muscles and Relevance with Botulinum Toxin Injections: A Pictorial Essay and Narrative Review.

Authors:  Wei-Ting Wu; Ke-Vin Chang; Hsiang-Chi Chang; Lan-Rong Chen; Chen-Hsiang Kuan; Jung-Ting Kao; Ling-Ying Wei; Yunn-Jy Chen; Der-Sheng Han; Levent Özçakar
Journal:  Toxins (Basel)       Date:  2022-01-27       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.